AXSM
Axsome Therapeutics, Inc.
$242.60
-1.71 (-0.70%)
At close · Jul 6
Market Cap
$12.48B
Shares
51,459,766
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$242.60
Open$245.40
Day$239.02–251.25
52W$96.09–260.19
Avg vol 30d978K
Short int3.3M · 6.4% float · 4.8d
Short vol39%
Last earningsMay 4, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 4
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+39% above
+
Price vs 50-day avg
+6% above
◦
RSI (14)
55 · neutral
−
MACD trend
negative
+
52-week position
89% · near high
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $230 › 200d $174 — 50d above 200d
−
Institutional flow
5 of 413 funds reported for Jun 30 · net -99 sh shares · +1 new
−
Insider flow
Net -$26.8M over 90 days · 100% sells
−
Short interest
6.38% of float · ▲ +6.1% MoM · 4.8 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
413 holders — near 3-yr high, broad support
Fundamentals
Strong
+
EPS growth
+39% Y/Y
−
Free cash flow
$-93.9M
+
Balance sheet
net cash $322.9M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 3, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 4, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+39% above
Bullish
Price vs 50-day avg
+6% above
Bullish
RSI (14)
55 · neutral
Neutral
MACD trend
negative
Bearish
52-week position
89% · near high
Bullish
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $230 › 200d $174 — 50d above 200d
Institutional flow
Distributing
5 of 413 funds reported for Jun 30 · net -99 sh shares · +1 new
Insider flow
Distributing
Net -$26.8M over 90 days · 100% sells
Short interest
Rising
6.38% of float · ▲ +6.1% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
413 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $96
Now $243 · 89%
52-wk high $260
vs 200-day avg +39%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| AUVELITY payer coverage across all channels | 86% | Q1 2026 | — |
|
|
|||
| AUVELITY prescriptions written | 223,000 | Q1 2026 | — |
|
|
|||
| SUNOSI payer coverage across all channels | 83% | Q1 2026 | — |
|
|
|||
| SUNOSI prescriptions written in the U.S. | 54,000 | Q1 2026 | — |
|
|
|||
| SYMBRAVO payer coverage expansion in commercial channel | 17M | effective May 2026 | — |
| SYMBRAVO prescriptions written | 17,000 | Q1 2026 | — |
| AUVELITY commercial coverage | 78% | Q1 2026 call | — |
| AUVELITY cumulative unique prescribers since launch | 60,000 | Q1 2026 call | — |
| AUVELITY discontinuation rate due to adverse reactions | 1.3% | Q1 2026 call | — |
| AUVELITY first-line first-switch prescriptions share | 56% | Q1 2026 call | — |
| AUVELITY HCP targets | 68,000 | Q1 2026 call | — |
| AUVELITY Medicare and Medicaid coverage | 100% | Q1 2026 call | — |
| AUVELITY net product revenue | $153.2M | Q1 2026 call | — |
| AUVELITY net product revenue year-over-year growth | 59% | Q1 2026 call | — |
| AUVELITY new prescribers activated | 5,500 | Q1 2026 call | — |
| AUVELITY prescriptions | 223,000 | Q1 2026 call | — |
| AUVELITY prescriptions year-over-year growth | 35% | Q1 2026 call | — |
| AUVELITY primary care share of prescribers | 35% | Q1 2026 call | — |
| AUVELITY sales force | 630 | Q1 2026 call | — |
|
|
|||
| AUVELITY total coverage across channels | 86% | Q1 2026 call | — |
| Avelity commercial coverage percent | 78% | Q1 FY2026 call | — |
| Avelity first-line first-switch prescriptions share of demand | 56% | Q1 FY2026 call | — |
| Avelity HCP targets | 68,000 | Q1 FY2026 call | — |
| Avelity new prescribers activated in quarter | 5,500 | Q1 FY2026 call | — |
| Avelity prescriptions | 223,000 | Q1 FY2026 call | — |
| Avelity primary care share of prescribers | 35% | Q1 FY2026 call | — |
| Avelity sales force | 630 | Q1 FY2026 call | — |
| Avelity total coverage percent of lives | 86% | Q1 FY2026 call | — |
| Avelity total unique prescribers since launch | 60,000 | since launch call | — |
| Simbravo new patients started on treatment | 5,000 | Q1 FY2026 call | — |
| Simbravo new payer contract lives covered | 17M | Q1 FY2026 call | — |
| Simbravo prescriptions | 17,000 | Q1 FY2026 call | — |
| Simbravo sales force | 150 | Q1 FY2026 call | — |
| SUNOSI net product revenue | $33.9M | Q1 2026 call | — |
| SUNOSI net product revenue year-over-year growth | 34% | Q1 2026 call | — |
| SUNOSI net product sales | $32.6M | Q1 2026 call | — |
| SUNOSI royalty revenue | $1.3M | Q1 2026 call | — |
| SYMBRAVO commercial channel coverage | 56% | Q1 2026 call | — |
| SYMBRAVO commercial payer contract covered lives | 17M | Q1 2026 call | — |
| SYMBRAVO government channels coverage | 57% | Q1 2026 call | — |
| SYMBRAVO net product sales | $4.1M | Q1 2026 call | — |
| SYMBRAVO neurology specialist share of prescriptions | 60% | Q1 2026 call | — |
| SYMBRAVO new patients starting treatment | 5,000 | Q1 2026 call | — |
| SYMBRAVO prescriptions | 17,000 | Q1 2026 call | — |
| SYMBRAVO prescriptions growth versus Q4 2025 | 36% | Q1 2026 call | — |
| SYMBRAVO primary care share of prescriptions | 32% | Q1 2026 call | — |
| SYMBRAVO sales force | 150 | Q1 2026 call | — |
| SYMBRAVO total payer coverage | 57% | Q1 2026 call | — |
| SUNOSI payer coverage in commercial channel | 96% | the fourth quarter | — |
| SUNOSI payer coverage in government channel | 60% | the fourth quarter | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AXSM
this stock
Axsome Therapeutics, Inc.
|
$12.48B | +32.8% | +65.5% | — | 6.4% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.92B | +16.8% | +46.2% | 31.1 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
|
ARGX
Argenx SE
|
$57.87B | +9.0% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AXSM | +0.4% | +4.8% | +43.2% | -0.9% | +32.8% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | -2.7% | +5.6% | +35.0% | -1.5% | +22.7% |